Novavax, Inc. (NVAX) 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
This summary covers the fiscal year ended December 31, 2025. Novavax is a biotechnology company focused on vaccine development, leveraging its proprietary Matrix-M™ adjuvant and recombinant nanoparticle technology. The company's primary commercial product is the Nuvaxovid™ COVID-19 vaccine. In 2025, Novavax transitioned the commercialization of its COVID-19 vaccine to Sanofi under a Collaboration and License Agreement (CLA), while continuing to supply existing Advance Purchase Agreement (APA) customers and partners. The company also advanced its pipeline, including COVID-19/Influenza combination candidates and the R21/Matrix-M™ malaria vaccine (partnered with Serum Institute of India).
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenue | $1.12 billion | $682.2 million | +$441.3 million |
| Net Income (Loss) | $440.3 million | ($187.5 million) | +$627.8 million |
| Diluted EPS | $2.58 | ($1.23) | +$3.81 |
| Operating Cash Flow | ($244.6 million) | ($87.3 million) | ($157.4 million) |
| Cash & Marketable Securities | $750.5 million | $938.2 million | ($187.7 million) |
| Total Debt (Convertible Notes) | $251.5 million | $175.3 million | +$76.2 million |
Note: Revenue includes significant one-time recognition from the termination of APAs with Canada ($575.7 million) and New Zealand ($27.3 million).
Material Changes vs. Prior Period
- Revenue Surge: Total revenue increased 65% year-over-year, driven primarily by the recognition of deferred revenue from the termination of the Canada APA and New Zealand APA, alongside increased product sales and Sanofi milestones.
- Profitability Turnaround: The company reported a net income of $440.3 million in 2025, reversing a net loss of $187.5 million in 2024. This was due to higher revenue and a significant reduction in operating expenses.
- Expense Reduction: Total expenses decreased by $260.4 million. Selling, General, and Administrative (SG&A) expenses dropped by $179.7 million due to cost containment measures and the sale of the Czech manufacturing facility in late 2024.
- Impairment Charges: A one-time impairment loss of $97.8 million was recorded in 2025 related to the corporate headquarters facility (700QO) classified as held for sale.
- Debt Restructuring: In August 2025, the company issued $225.0 million of 2031 Convertible Notes, exchanging a portion of its 2027 Notes, resulting in a $28.7 million loss on debt extinguishment.
Guidance, Outlook, and Risks
- Strategic Partnerships:
- Sanofi: Sanofi now leads global commercialization of Nuvaxovid. Novavax earned $225 million in milestones in 2025. Remaining milestones total up to $425 million for COVID-19 and combination products.
- Pfizer: In January 2026, Novavax entered a license agreement with Pfizer for Matrix-M™ use in two infectious disease areas, receiving a $30 million upfront payment with up to $500 million in potential milestones.
- Takeda: An amended agreement in April 2025 secured a tiered royalty structure for the Japanese market.
- Supply Agreements (APAs):
- Australia: Regulatory challenges led to a withdrawal of the vaccine application in Q3 2025. Up to $92.5 million of deferred revenue may become refundable if regulatory approval for the updated vaccine is not achieved by contractual deadlines.
- UK: A settlement agreement requires Novavax to refund $123.8 million to the UK government over three years.
- Liquidity: Management believes current cash, cash equivalents, and marketable securities ($750.5 million as of Dec 31, 2025), combined with expected revenue, are sufficient to fund operations for at least the next 12 months. A new $330 million credit facility was secured in February 2026, with $50 million drawn at closing.
- Risks: Key risks include the uncertainty of regulatory approvals for updated COVID-19 variants (specifically in Australia), reliance on third-party manufacturers (Serum Institute of India), potential refund obligations under APAs, and the need for continued funding to support pipeline development.
Key Facts for Investor Verification
- Revenue Quality: Verify the sustainability of revenue streams post-2025, as a significant portion ($603 million) was derived from one-time APA terminations (Canada/New Zealand) rather than recurring product sales.
- Australia APA Status: Monitor the outcome of discussions with the Australian government regarding the withdrawn vaccine application and the potential refund of up to $92.5 million in deferred revenue.
- Sanofi Milestone Timing: Track the achievement of the remaining $425 million in Sanofi milestones, particularly the $75 million tied to the completion of technology transfer.
- Debt Covenants: Review the covenants in the new February 2026 Credit Agreement, specifically the requirement to maintain unrestricted cash of at least $100 million and potential royalty revenue triggers for additional tranches.
- UK Refund Liability: Confirm the cash outflow schedule for the $123.8 million settlement payment to the UK government, with quarterly installments beginning in 2025 and ending in 2027.